NatureOctober 1, 2026Trial readout
Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial
Reported by Nature. Read the original →
What the story says
The headline reports on a randomized placebo-controlled trial investigating the effects of semaglutide on kidney disease in individuals with type 2 diabetes.
Summarised by a model from Nature's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
SemaglutideA · Human clinical
- Insulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.Human · RCT · 2026
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Human · RCT · 2026
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?Human · Case report · 2026
What the headline doesn't tell you
- Semaglutide has 60 studies on file, 32 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.